Resources & Guides

Retatrutide side effects guide: nausea, diarrhea, and other GI symptoms from Phase 2 clinical trial data, plus management strategies.

People search "GLP-3 retatrutide" after hearing the nickname online. There is no GLP-3 receptor. Retatrutide is a triple agonist hitting GLP-1, GIP, and glucagon. Here is where the name came from and what it means.

An educational, pharmacokinetics-grounded explainer of what a tirzepatide to retatrutide transition involves: washout timing, the 2mg restart, GI reset, and the investigational reality.

Retatrutide does not prevent lean mass loss, but the proportion lost is similar to other obesity treatments. Here is what the DEXA data shows, why the glucagon receptor is only a hypothesis, and what actually protects muscle.

The TRIUMPH-1 secondary dataset presented at ADA 2026 goes beyond weight loss. Triglycerides fell 41.0%, non-HDL cholesterol 24.2%, systolic blood pressure 12.3 mmHg, and nested substudies showed up to 73.1% less knee pain and up to 60.6% less sleep apnea on retatrutide 12mg.

A practical retatrutide nausea management guide covering the mechanism, Phase 2 trial data, the dose step-back protocol, and dietary strategies.

A dose-by-dose breakdown of retatrutide phase 3 weight loss results from the TRIUMPH program: TRIUMPH-1 (28.3% at 80 weeks), the 104-week extension (30.3%), TRIUMPH-4 (28.7%), safety data, and what investigational status means for access.

A side-by-side look at the single, dual, and triple agonists. Trial weight loss runs 14.9% (semaglutide), 20.9% (tirzepatide), and 24.2% (retatrutide), but the trials differ and only one pairing has a head-to-head study.

Retatrutide activates three hormone receptors at once. Here is what it actually does inside the body: appetite suppression, metabolic shifts, blood sugar regulation, and fat loss, all grounded in published Phase 2 data.

Retatrutide is not commercially available. It is in Phase 3 trials with expected FDA approval in 2027-2028. Current access: clinical trials (free), compounded pharmacies ($200-500/mo), or research peptides ($150-500/mo). Here is everything you need to know about retatrutide availability worldwide.

Complete GLP-3 retatrutide dosage chart showing the Phase 2/3 clinical trial titration from 2mg to 12mg weekly. Includes what to expect at each dose, weight loss results by tier, side effects data, printable download, and free dosing calculator.

How much weight can you lose on retatrutide? This guide covers Phase 3 and Phase 2 clinical data, a month-by-month timeline, cross-drug comparison to tirzepatide and semaglutide, body composition breakdown, and what individual factors affect your results.

Retatrutide achieved 24.2% weight loss vs tirzepatide's 20.9%. Compare mechanisms, trial results, side effects, and find out which medication might work better for you.

Retatrutide has no official price. It's still in Phase 3 clinical trials. This guide covers what people actually pay today for research peptides and compounded retatrutide, what it will likely cost at commercial launch, and how it compares to tirzepatide and semaglutide.

Retatrutide isn't FDA-approved yet, but people are accessing it now through three main routes. This guide covers how to get retatrutide via clinical trials, compounding pharmacies, and research peptide vendors, plus what you need to know about safety, legality, and costs.

Retatrutide achieved 24.2% weight loss vs semaglutide's 14.9% in trials. Compare triple-agonist vs single-agonist mechanisms, approval status, clinical data, side effects, and find out which GLP-1 medication is right for you.

Retatrutide results from clinical trials show 24.2% weight loss at 48 weeks with the 12mg dose. Detailed breakdown of trial data, timeline of results, body composition changes, and realistic expectations.

Retatrutide is the first triple agonist that activates GIP, GLP-1, and glucagon receptors at once. How each receptor contributes to weight loss, why it outperforms single and dual agonists, and what the clinical data shows.

Retatrutide is an investigational triple-agonist medication that activates GLP-1, GIP, and glucagon receptors. Phase 2 trials showed 24.2% weight loss, the highest ever recorded for a GLP-1 class drug. Learn everything about this breakthrough medication.